Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) Sellers Reduced Their Shorts By 3.63%

May 16, 2018 - By Mary Kidd

Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) noted a decrease of 3.63% in shares shorted. FINRA announced shares shorted of ARCT’s total 87,600 shares. That’s 3.63% down from 90,900 shares. Former ARCT’s position will need 3 days to restore. It has 29,200 average volume.

The stock increased 4.22% or $0.24 during the last trading session, touching $5.93.Arcturus Therapeutics Ltd. has volume of 18,450 shares. Since May 16, 2017 ARCT has declined 30.95% and is downtrending. ARCT underperformed the S&P 500 by 42.50%.

Arcturus Therapeutics Ltd. operates as an RNA medicines company.The company has $ market cap. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.Currently it has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

For more Arcturus Therapeutics Ltd. (NASDAQ:ARCT) news brought out briefly go to:,,, or The titles are as follows: “Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board’s Egregious Attempt to Dilute Shareholders” brought out on May 02, 2018, “Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary …” on May 14, 2018, “Arcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tactic” with a publish date: April 23, 2018, “Arcturus Therapeutics Files Form 20-F” and the last “Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities …” with publication date: April 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: